XML 78 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration and License Agreements - Bayer Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Disaggregation of Revenue [Line Items]                      
Revenues $ 1,927.8 $ 1,663.5 $ 1,608.0 $ 1,511.5 $ 1,582.4 $ 1,500.7 $ 1,470.1 $ 1,319.0 $ 6,710.8 $ 5,872.2 $ 4,860.4
Bayer                      
Disaggregation of Revenue [Line Items]                      
Minimum advance notice required to terminate collaboration agreement                 6 months    
Maximum advance notice required to terminate collaboration agreement                 12 months    
Percentage of repayment of development balance out of profits                 50.00%    
Contingent reimbursement obligation $ 265.0               $ 265.0    
Ang2 antibody | Bayer                      
Disaggregation of Revenue [Line Items]                      
Up-front payment received         $ 37.4           50.0
Ang2 antibody and PDGFR-beta antibody | Bayer                      
Disaggregation of Revenue [Line Items]                      
Revenues                   $ 63.8 $ 33.5
Minimum | Bayer                      
Disaggregation of Revenue [Line Items]                      
Revenue based on percentage of annual sales in Japan                 33.50%    
Maximum | Bayer                      
Disaggregation of Revenue [Line Items]                      
Revenue based on percentage of annual sales in Japan                 40.00%